drugset / Trial / NCT04374877
Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is a Phase 1/1b, open-label, first-in-human, dose-escalation and expansion study of CHS-388, a monoclonal antibody that targets IL-27, as a monotherapy and in combination in patients with solid tumors.
Timeline
- Start
- 2020-04-22
- Primary completion
- 2025-05-28
- Completion
- 2025-06-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Casdozokitug | Monoclonal antibody | — | — |
| Background | Pembrolizumab | Monoclonal antibody | — | Intravenous |
| Background | Toripalimab | Monoclonal antibody | — | Intravenous |